FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

about

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Item

http://www.wikidata.org/entity/Q47419522

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

FOXP1 expression is a prognost ...... th rituximab and chemotherapy.

@en

FOXP1 expression is a prognost ...... th rituximab and chemotherapy.

@nl

type

Item

label

FOXP1 expression is a prognost ...... th rituximab and chemotherapy.

@en

FOXP1 expression is a prognost ...... th rituximab and chemotherapy.

@nl

prefLabel

FOXP1 expression is a prognost ...... th rituximab and chemotherapy.

@en

FOXP1 expression is a prognost ...... th rituximab and chemotherapy.

@nl

P1476

FOXP1 expression is a prognost ...... ith rituximab and chemotherapy

@en

P2093

Andreas Rosenwald

http://www.w3.org/2001/XMLSchema#string

Heike Horn

http://www.w3.org/2001/XMLSchema#string

Laurie H Sehn

http://www.w3.org/2001/XMLSchema#string

Michael Boesl

http://www.w3.org/2001/XMLSchema#string

Vindi Jurinovic

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hiddemann

http://www.w3.org/2001/XMLSchema#string

Wolfram Klapper

http://www.w3.org/2001/XMLSchema#string

P2860

WGCNA: an R package for weighted correlation network analysis

The Polycomb group protein EZH2 directly controls DNA methylation

FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

P304

226-235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2017-08-799080

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29122756

http://www.w3.org/2001/XMLSchema#string

P932

5757687

http://www.w3.org/2001/XMLSchema#string